TCTAP A-203 the “4S” Law for the Management of Iatrogenic Aortocoronary Dissection: Clinical Results and Importance of Immediate Bail-out Stenting

Shao-Ping Nie,Edmundo Patricio Lopes Lao,Xiao Wang,Yan Qiao,Chang-Sheng Ma

DOI: https://doi.org/10.1016/j.jacc.2014.02.246

IF: 24

2014-01-01

Journal of the American College of Cardiology

Abstract:Background: Although statin therapy is beneficial for vascular diseases, the relationship between specific statin therapy and incidence of new-onset diabetes mellitus (DM)remains uncertain. We evaluated the impact of Simvastatin therapyon the development of new-onset DM from3-year clinicalfollow up datain a series of Asian population. Methods: A total of 3,436 consecutive patients who did not have DM were enrolled. New-onset DMwas defined as having a fasting blood glucose 126mg/dLor HbA1c 6.5%. Baseline characteristics between the Simvastatin and the control group were propensity score matched (PSM, C-statics1⁄40.808). Three-year cumulative incidence of new-onset DM was compared between the two groups. Results: At baseline, patients in the Simvastatin group showed higher prevalence ofelderly, male gender,dyslipidemia, coronary artery disease, smoking and alcoholic history, and higher levels of HbA1c, fasting glucose, triglyceride, fibrinogen, and ALP. Three-year clinical follow up results showed a higher incidenceof new-onset DM in the Simvastatin group (3.8% vs. 2%, p1⁄40.017). Following PSM (C-statics1⁄40.808), the 2 groups were well balanced except for higher levels of fibrinogen, ALT, and ALP in the Simvastatin group. After adjustment, there was no difference in the incidence of new-onset DMbetween the 2 groups up to 3years (Figure). Conclusion: In our study, the relationship between the use of Simvastatin and the incidence of new-onset DM remains unclear. Long-term follow up with a larger study population will be necessary for further information.